Skip to main content
. Author manuscript; available in PMC: 2013 May 1.
Published in final edited form as: Pediatr Blood Cancer. 2011 Jul 25;58(5):708–714. doi: 10.1002/pbc.23254

Table II.

Patient Total daily
cyclophosphamide
dose (mg)
Cyclophosphamide
AUC
(mcg/ mL * hr)
DNA adduct AUC
(adducts/ 10^6
nucleotides * hr)
Ratio of
DNA adduct AUC
/cyclophosphamide AUC
Non-FA n=9

1 5640 515.3 96.7 0.19
2 4000 529.2 142.8 0.27
3 4600 659.6 425.3 0.64
4 3700 908.7 276.0 0.30
5 2750 868.0 19.0 0.02
6 3000 647.4 33.5 0.05
7 4450 463.0 50.8 0.11
8 3400 961.0 147.0 0.15
9 3000 300.6 177.4 0.59

Median (range) 3850 (2750–5640) 659.6 (300.6–908.7) 144.9 (19.0–425.3) 0.20 (0.02–0.64)

FA n=9

1 115 4.2 64.3 15.16
2 195 8.1 36.1 4.43
3 210 82.3 26.3 0.32
4 206 167.5 171.3 1.02
5 100 134.9 148.7 1.10
6 95 39.7 141.2 3.55
7 165 81.6 271.5 3.33
8 93 49.3 72.4 1.47
9 190 33.6 99.8 2.97
Median (range) 140 (93–210) 49.3 (4.2–167.5) 99.8 (26.3–271.5) 3.0 (0.32–15.16)

p-value* <0.001 <0.001 0.47 0.05
*

P-values are comparison of non-FA and FA pharmacokinetic measures.